Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05253495 · ClinicalTrials.gov registry record · Phase 2
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
A Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by New York Medical College.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 3
- Study locations
NCT05253495: Recruiting Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by New York Medical College.
NCT05253495 is a Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma that is actively recruiting participants, run by New York Medical College. The registered enrollment target is 80 participants, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (52% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05253495, a Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, is actively recruiting participants, sponsored by New York Medical College.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 3
- Study locations
Study Summary
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).
Primary Outcome
to evaluate the DLTs of polatuzumab vedotin (Pv) in combination with rituximab (RTX) containing French-American-British (FAB) chemoimmunotherapy, with reduced dose anthracycline to MB-NHL
Conditions Studied
Interventions
- DRUG DOC Group B
- DRUG Pv-COMRAD 1 and 2 Group B
- DRUG Pv-R-CYM 1 and 2 Group B
- DRUG DOC Group C
- DRUG MAD CPR 1 and 2
Study Locations (3)
Alabama
- University of Alabama - Birmingham
Florida
- University of Flordia - Gainsville
New York
- New York Medical College - Vallhala
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What NCT05253495 shows while recruiting
NCT05253495 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (52% lower).
The record links to 2 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which DOC Group B is the first listed.
NCT05253495 reports a single indexed study location in Alabama, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05253495 about?
NCT05253495 is a clinical study titled "Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma". The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cH...
What is the current status of trial NCT05253495?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2022-02-01. Estimated completion is 2028-06-30.
What conditions does trial NCT05253495 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Hodgkin Lymphoma.
What interventions are being tested in trial NCT05253495?
The interventions under investigation include: DOC Group B (DRUG), Pv-COMRAD 1 and 2 Group B (DRUG), Pv-R-CYM 1 and 2 Group B (DRUG), DOC Group C (DRUG), MAD CPR 1 and 2 (DRUG).
Who is sponsoring clinical trial NCT05253495?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05253495 being conducted?
This trial has 3 study locations across Alabama, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05253495's enrollment target sits among peer trials
80 43rd of 106 higher than 64 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI